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Abstract 
Anaplasma phagocytophilum is the agent of tick‑borne fever, equine, canine and human granulocytic anaplasmosis. 
The common route of A. phagocytophilum transmission is through a tick bite, the main vector in Europe being Ixodes 
ricinus. Despite the apparently ubiquitous presence of the pathogen A. phagocytophilum in ticks and various wild and 
domestic animals from Europe, up to date published clinical cases of human granulocytic anaplasmosis (HGA) remain 
rare compared to the worldwide status. It is unclear if this reflects the epidemiological dynamics of the human infec‑
tion in Europe or if the disease is underdiagnosed or underreported. Epidemiologic studies in Europe have suggested 
an increased occupational risk of infection for forestry workers, hunters, veterinarians, and farmers with a tick‑bite his‑
tory and living in endemic areas. Although the overall genetic diversity of A. phagocytophilum in Europe is higher than 
in the USA, the strains responsible for the human infections are related on both continents. However, the study of the 
genetic variability and assessment of the difference of pathogenicity and infectivity between strains to various hosts 
has been insufficiently explored to date. Most of the European HGA cases presented as a mild infection, common 
clinical signs being pyrexia, headache, myalgia and arthralgia. The diagnosis of HGA in the USA was recommended to 
be based on clinical signs and the patient’s history and later confirmed using specialized laboratory tests. However, 
in Europe since the majority of cases are presenting as mild infection, laboratory tests may be performed before the 
treatment in order to avoid antibiotic overuse. The drug of choice for HGA is doxycycline and because of potential for 
serious complication the treatment should be instituted on clinical suspicion alone.
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Background
Researchers interest on tick-borne pathogens (TBPs) has 
increased during the last decades with recognition of new 
agents, e.g. Neoehrlichia mikurensis and “Candidatus 
Anaplasma camelii” [1–3] and expansion of established 
tick-borne pathogens, driven by factors such as climatic 
changes and altered land use [4, 5]. TBPs dynamics, espe-
cially occurrence and abundance, are multifactorial, and 
strongly influenced by ecological interactions of tick spe-
cies and their vertebrate hosts. The pivotal impact of cli-
mate change upon the geographical distribution of ticks, 
their abundance and host feeding patterns has become 
increasingly recognised [4–6] together with social 
changes, globalisation and intercontinental traveling of 
humans and animals influencing both the geographical 
distribution and abundance of ticks and pathogens [6].
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Genus Anaplasma (Rickettsiales: Anaplasmataceae) is 
comprised of various species capable of causing disease 
among a variety of vertebrate hosts, including humans. 
The currently recognized species are Anaplasma bovis, 
A. centrale, A. marginale, A. phagocytophilum, A. platys, 
A. ovis and the more recently described A. odocoilei and 
A. capra [7–9]. These small pleomorphic Gram-negative 
bacteria (0.2–1.5 µm) are obligate intracellular microbes 
primarily transmitted by ticks [10]. Anaplasma phagocy-
tophilum, the agent of granulocytic anaplasmosis, from a 
human perspective, is considered one of the most impor-
tant species as a result of its zoonotic potential [11]. It is 
the etiological agent of tick-borne fever (TBF) in rumi-
nants and of equine, canine and human granulocytic 
anaplasmosis (EGA, CGA and HGA, respectively) [7, 
12]. Infections with A. phagocytophilum in animals are 
commonly reported in the northern hemisphere, being 
among the most widespread TBP in Europe [13]. Moreo-
ver, the geographical distribution of the pathogen and its 
main vector (Ixodes ricinus) are increasing in latitude and 
altitude [13] covering almost the entire territory of conti-
nental and Atlantic Europe.
Genetic diversity is being increasingly recognised 
amongst European strains of A. phagocytophilum dem-
onstrated through phylogenetical analysis of genes such 
as groEL (chaperone protein encoding gene) [14–16], 
ankA (cytoplasmic protein antigen with ankyrin repeats 
encoding gene) [17–21] and msp4 (major surface pro-
tein 4 encoding gene) [22]. GroEL gene is one of the 
two genes belonging to the heat shock operon groESL 
which encodes for the expression of highly conserved 
heat-shock proteins [23]. GroEL gene is considered a 
suitable marker to discriminate between A. phagocyt-
ophilum ecotypes distinguishing variants of different 
pathogenicity or geographical origin better than the 
16S RNA locus [16]. The ankA gene encodes a protein 
which has repeated ankyrin motifs. It might be a viru-
lence factor and it has been hypothesized to be involved 
in host adaptation underlying diversifying selection [19, 
21, 23]. Sequencing ankA distinguishes variants accord-
ing to their animal hosts, this gene having a higher 
sequence variability compared to groEL and msp4 [17, 
22]. Both msp2 and msp4 belong to the OMP-1/MSP2/
P44 superfamily [23]. The msp4 sequence seems to be 
stable through the A. phagocytophilum life-cycle being a 
preferable genetic marker for phylogenetic analyses [22]. 
Sequences analysis showed a high degree of identity at 
the msp4 locus, similar to the results using the groESL 
with the exception of roe deer strains, these being more 
diverse even than using ankA [22]. Different authors 
published studies of genetic variants using different ter-
minology, such as ecotype (groEL), cluster (ankA) or 
genotype (msp4) [16, 20, 21]. “Ecotype” refers to hosts 
specificity of certain genotypes; “cluster” involves a 
deeper phylogenetic approach, while “genotype” is based 
on a purely genetic analysis. To refer to all mentioned 
terms, “genetic group” is used here. Different correlations 
of genetic variants have been found amongst vertebrate 
hosts, tick vectors and geographical locations. Infected 
humans, whether from Europe or America seem to share 
related strains belonging to the same genetic group [16, 
20, 21]. Domestic animals like horses, dogs and cats, wild 
animals like red deer (Cervus elaphus), wild boars (Sus 
scrofa), red foxes (Vulpes vulpes) and hedgehogs (Erina-
ceus spp.) are harbouring strains with zoonotic potential 
related with human strains, while roe deer (Capreolus 
capreolus), rodents and birds seem to carry genetically 
distant strains [16, 19–21]. Regarding the strains infect-
ing domestic ruminants, the studies present different 
results depending on the gene used for the analysis [16, 
19–21] leading to some uncertainty about their possible 
involvement in the epidemiology of zoonotic infections. 
Further studies are necessary to establish which approach 
is discriminatory enough to discern between hosts with 
or without relevance to the epidemiology of HGA, espe-
cially since new highly discriminatory approaches such as 
multilocus sequence typing (MLST) and multiple-locus 
variable-number tandem repeat analysis (MLVA) are cur-
rently used [21, 24]. For instance, the MLST analysis on 
seven housekeeping genes (pheS, glyA, fumC, mdh, sucA, 
dnaN and atpA) revealed a similar pattern with ankA 
gene analysis, with strains from humans, dogs, horses, 
wild boar and hedgehogs belonging to the same clonal 
complex while other strains belonged to another seven 
clonal complexes [21]. The MLVA technique developed 
by Dugat et al. [24] showed the presence of slightly differ-
ent profiles among the same host species (e.g. cattle) and 
different profiles between different hosts [24]. Based on 
this analysis, two epidemiological cycles were suggested 
for France, one involving red deer as reservoir hosts and 
domestic ruminants as either accidental or longer-term 
hosts, and another involving roe deer as reservoir hosts 
[24]. However, this study was based on a limited number 
of samples and a low variety of hosts, and further analy-
sis could reveal the presence of multiple epidemiological 
cycles.
Despite the increasing number of studies on A. 
phagocytophilum genetic diversity, there are still insuf-
ficient data to understand the geographical distribu-
tion, host preferences and pathogenicity to humans of 
each described genetic variant. In this context, it is hard 
to analyse the relevance of these genetic groups for the 
public health. Moreover, despite several recent reviews, 
epidemiological data regarding human infections in 
Europe are poorly collated consisting of a collection 
of case reports and seroprevalence studies. The HGA 
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epidemiology in Europe has not been critically reviewed. 
In this context, the aim of this review was to update epi-
demiological knowledge on European HGA, compar-
ing this with what is known from the USA and to review 
diagnostic approaches.
Anaplasma phagocytophilum (Foggie, 1949)
The microorganism and its variability in Europe
Anaplasma phagocytophilum infection has been 
described under various acronyms according to the main 
species affected (TBF, EGA, CGA and HGA) [7, 11]. Ana-
plasma phagocytophilum infects mammalian neutro-
phils, where it replicates within cell membrane derived 
cytoplasmatic vacuoles named morulae [25, 26]. Moru-
lae may contain one or more reticulate cells, dense cored 
cells, or both [26].
Anaplasma phagocytophilum has a single small circular 
chromosome (1.47  Mb) with abundant repeats (12.7%) 
that has been suggested to facilitate antigenic variation 
through recombination [15]. Of its 1369 open reading 
frames, 462 are unique encoding hypothetical, conserved 
hypothetical and conserved domain proteins, membrane 
proteins and lipoproteins [27–31]. Phylogenetic analyses 
of genes such as groEL [14–16], ankA [17–21] and msp4 
[22] of the European strains suggest the presence of dif-
ferent genetic variants and a correlation of these with the 
vertebrate hosts, tick vectors and also a possible correla-
tion with geographical origin.
Regardless the gene used for analysis, infected humans, 
whether European or American, revealed the same 
genetic group [16, 20, 21]. Similarly, domestic animals 
like horses, dogs, and cats, share the same ecotype/clus-
ter (I) with humans based upon phylogenetic analysis of 
groEL and ankA [16, 19–21]. Conversely, using a more 
discriminatory ankA gene analysis [32], revealed that 
dogs were infected with three different strains, one being 
the above-mentioned human variant and two different 
canine variants. Furthermore, ankA sequence analy-
sis of infections of cattle, sheep and goats disclosed two 
strains belonging to clusters I and IV [19, 21]. Although 
A. phagocytophilum was also detected in others domes-
tic animals, like donkeys [33], there are no data regarding 
the strain involved.
European wild ruminant infection displays yet fur-
ther diversity of infecting ecotypes, clusters or geno-
types including ecotype/cluster I [16, 19, 21]. Anaplasma 
phagocytophilum was detected in roe deer (Ca. capreo-
lus) [19, 34], red deer (Ce. elaphus) [13, 35] and in Ibe-
rian red deer (Ce. elaphus hispanicus) [36]. It was also 
detected in fallow deer (Dama dama), sika deer (Ce. nip-
pon) and Dybowskiʼs sika deer (Ce. nippon hortulorum), 
reindeer (Rangifer tarandus), elk (Alces alces), European 
bison (Bison bonasus), chamois (Rupicapra rupicapra), 
alpine ibex (Capra ibex), and mouflon (Ovis musimon) 
with variable prevalence [13, 24, 37, 38]. Among these, 
the red deer are considered one of the reservoir hosts for 
the human pathogenic strain, based on groEL sequence 
analysis belonging to ecotype I [16, 39]. Use of a more 
discriminatory ankA sequence revealed infection with 
strains belonging to cluster I and IV, and less in cluster 
III amongst red deer [19–21]. In contrast, roe deer seem 
to be infected mainly by strains belonging to ankA gene 
clusters II, III and less so by strains belonging to cluster 
IV [19–21] and by strains belonging to groEL ecotype 
II and a few strains belonging to ecotype I [16]. AnkA 
sequences from European bison and chamois mirror the 
strains found in red deer, belonging to clusters I and IV 
[19–21]. Whereas, mouflon share the same ecotype I 
with human strains based upon groEL analysis [16].
Limited reports have suggested wild boar (S. scrofa) as 
a potential reservoir hosts for A. phagocytophilum [40] 
with ankA, groEL and msp4 gene analysis suggesting an 
overlap of clusters, ecotypes or genotypes with those of 
human significance [16, 21, 32].
Similarly to dogs, sequences obtained in wild carni-
vores, including red fox (V. vulpes), brown bear (Ursus 
arctos) and one timber wolf (Canis lupus occidentalis) 
cluster with human strains (cluster/ecotype/genotype I) 
using ankA, groEL and msp4 sequences [16, 21, 32, 41].
Small mammals have been considered reservoir hosts 
for A. phagocytophilum [42] with infection reported in 
mice, voles and shrews [13, 16, 43–50], but their short 
life-span is likely to reduce their epidemiological impor-
tance as reservoir hosts, but this remains hotly debated 
[48]. Subsequent studies of A. phagocytophilum associ-
ated with I. trianguliceps and rodents, suggest distinct 
enzootic cycles [20, 44–47]. Infected voles and shrews 
revealed a distinct cluster V of A. phagocytophilum [20, 
21]. There are also several reports regarding the occur-
rence of A. phagocytophilum infection in European 
hedgehogs (Erinaceus europaeus) [21, 51, 52], northern 
white-breasted hedgehog (E. roumanicus) [53] and black 
rat (Rattus rattus) [54]. Based on both ankA and groEL 
analysis, these hedgehog strains belonged to cluster I [16, 
21]. In addition to these, A. phagocytophilum was also 
detected in European hares (Lepus europaeus) [55] and 
large rodents such as the crested porcupine (Hystrix cris-
tata) [56] but phylogenetic data regarding these strains 
are limited.
A further lack of clarity surrounds infection of avian 
hosts with A. phagocytophilum. A distinct ecotype (IV) 
was reported in ticks collected from blackbirds (Turdus 
merula), suggesting the existence of a separate enzo-
otic cycle for A. phagocytophilum in birds and probably 
utilizing I. frontalis ticks [16]. Nevertheless, birds are 
additionally important hosts for immature I. ricinus, 
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which are also the main ticks biting humans [48], thus 
of public health relevance.
The data on the geographical distribution of the sum-
marized genetic variants are limited. The known geo-
graphical distribution of the genetic group containing 
strains with zoonotic potential is presented in Fig.  1. 
The hosts harbouring these strains and their geographi-
cal origin are presented in Table  1. Based on all these 
studies, the genetic group including human strains 
seems to be the most diverse and widespread [16, 17, 
19–21]. In one of these studies the geographical dis-
tribution of each ecotype is presented [16]. In contrast 
with ecotype I, which seems to be spread in almost all 
Europe, the remaining ecotypes (II–IV) have a more 
limited distribution. Although their distribution over-
laps with that of ecotype I [16], the limited distribution 
of the ecotypes II–IV may be influenced by the lim-
ited origin of the samples tested. In order to clarify the 
spread of each genetic group further studies should be 
performed.
This high diversity may be the result of an adaptation 
of A. phagocytophilum to different host species. Moreo-
ver, the co-infection of vectors with multiple genetic 
variants as it was suggested before in roe deer [57], may 
lead to the occurrence of new strains with different host 
preferences. The impact of strain heterogeneity on pub-
lic health is not enough explored. However, the possible 
existence of independent enzootic cycles should decrease 
the pressure on human health.
In contrast with the heterogeneity of the European 
strains, American strains of A. phagocytophilum appear 
more restricted, primarily belonging to two variants 
(AP-ha and AP-V1), of which only AP-ha was detected 
in humans [13, 22]. However, a comparison between 
pathogenic and non-pathogenic strain diversity from the 
two continents is unsubstantiated since the hypothesis 
Fig. 1 The geographical distribution of HGA cases and genetic groups including strains with zoonotic potential. Notes: 1Andora, Monaco, San 
Marino, Vatican; *Detected in various hosts (details presented in Table 1) [19, 21]; **Detected in various hosts (details presented in Table 1) [22, 32]. 
*** Detected in various hosts (details presented in Table 1) [16, 145]
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Table 1 The hosts harbouring strains with zoonotic potential and their geographical origin
Abbreviations: AT, Austria; BE, Belgium; CZ, Czech Republic; DE, Germany; DK, Denmark; EE, Estonia; ES, Spain; FI, Finland; FR, France; GB, UK; HR, Croatia; HU, Hungary; 
IT, Italy; LU, Luxembourg; NL, Netherlands; PO, Poland; PT, Portugal; SE, Sweden; SI, Slovenia; SK, Slovakia; AL, Albania; CH, Switzerland; NO, Norway
Common name Scientific name Origin Genetic group (gene) References
Bison Bison bonasus PO Cluster I
(ankA)
[19, 21]
Cow Bos taurus NO, EE
Cat Felis catus AT, CH
Chamois Rupicapra rupicapra SI
Dog Canis familiaris CH, DE, DK, ES, FR, SE, SI, SK
Hedgehogs Erinaceus europaeus DE
Horse Equus caballus CH, DE, DK, NL
Human Homo sapiens SI
Red deer Cervus elaphus DE, PO, SI
Red fox Vulpes vulpes DE
Sheep Ovis aries DE, NO
Wild boar Sus scrofa SI
Brown bear Ursus arctos SI Genotype I
(msp4)
[22, 32]
Dog Canis familiaris SI
Donkey Equus africanus asinus DE
Horse Equus caballus DE
Human Homo sapiens SI
Wild boar Sus scrofa SI
Alpine ibex Capra ibex AT Ecotype I
(groEL)
[16, 145]
Beech marten Martes foina BE
Badger Meles meles BE
Brown bear Ursus arctos HR, SI
Caw Bos taurus FR, DE, NL, CH
Cat Felis catus FI
Chamois Rupicapra rupicapra AT, HR, SI
Common blackbird Turdus merula CZ
Dog Canis familiaris AL, HR, FI, DE, HU, IT, SI
European hare Lepus europaeus HR
European polecat Mustela putorius BE
Fallow deer Dama dama DE, NL, SK
Gray wolf Canis lupus HR
Hedgehogs Erinaceus europaeus CZ, DE, HU
Horse Equus caballus HR, CZ, FR, DE, IT, NL, SE
Human Homo sapiens AT, BE, NL, PO, SI
Mouflon Ovis musimon AT, HR, DE, NL, SK
Mouse Alces alces NO, SE
Red deer Cervus elaphus AT, HR, DE, NL, NO, PO, SI, ES
Red fox Vulpes vulpes HR, DE, NL
Red squirrel Sciurus vulgaris CZ
Roe deer Capreolus capreolus HR, FR, DE, NL, PO, SI, CH
Sheep Ovis aries HR, FR, NL, NO, GB
Sika deer Cervus nippon DE
Wild boar Sus scrofa HR, NL, SI, SK
Wild goat Capra aegagrus DE, NL, GB, CH
Only in vectors I. ricinus EE, LU, PT
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referring to non-pathogenic strains is not based on exper-
imental data but on the lack of detection in humans.
In contrast with the European situation, in the USA 
human strains are maintained in nature through reser-
voir hosts such as white footed mice (Peromyscus leuco-
pus), deer mice (P. maniculatus) and other rodents [13, 
58, 59]. White-tailed deer (Odocoileus virginianus) are 
considered major reservoir hosts for variants which were 
never detected in humans, being suggested as non-path-
ogenic [13, 22]. Based on different markers (ankA, groEL, 
gltA and msp4 genes), American and European human 
strains are grouped in different clades, being phylogeneti-
cally distinct [21, 22, 60]. However, based on ankA gene 
analysis, both European and American strains belong to 
the same genotype I, suggesting a degree of relatedness 
[19]. Whether differences in virulence and clinical mani-
festations observed between the American and European 
strains reside within their genetic composition or differ-
ences are driven by their eco-epidemiology remains to be 
resolved.
Transmission and vectors
Transmission of A. phagocytophilum commonly occurs 
through the bite of an infected tick. Ixodes ricinus serves 
as the main vector in Europe [61, 62]. Transstadial trans-
mission is important in maintaining A. phagocytophilum 
within its endemic cycles [6, 16, 49]. Although transo-
varial transmission has been suggested, its efficacy seems 
to be low [16, 49], necessitating further amplification by 
feeding upon reservoir species to maintain the bacteria 
in endemic cycles [49, 62]. Ixodes ricinus may become 
infected with A. phagocytophilum after feeding on an 
infected host, depending on various factors such as the 
percentage of infected neutrophils and the density of 
ticks feeding on the same host [63]. Co-feeding transmis-
sion from infected to uninfected ticks whilst feeding at 
common sites has not yet been reported for Anaplasma 
[64].
In addition to its main vectors, A. phagocytophilum 
has been detected in questing ticks belonging to other 
members of genus Ixodes including the European I. per-
sulcatus [65], I. trianguliceps [66], I. ventalloi [67] and 
I. hexagonus [68]. Beyond Ixodes, A. phagocytophilum 
DNA has been detected in Dermacentor reticulatus [69], 
Haemaphysalis punctata, H. concinna, and Rhipicephalus 
bursa [70]. The vectorial capacity or these other Euro-
pean tick species has not been fully elucidated.
Despite regular detection of A. phagocytophilum 
DNA in I. ricinus in Europe, reports of infected ticks 
removed from humans are infrequent, being reported 
in Poland [71], Italy [49, 72], Romania [73] and the 
UK [74]. Among these, only in the UK study, the pres-
ence of A. phagocytophilum in two of the three ticks 
removed from a patient with non-specific clinical signs 
was demonstrated [74]. The patient developed clini-
cal signs 3 days after the tick bite and was serologically 
diagnosed with HGA in accordance with CDC criteria 
by a 4-fold increase of A. phagocytophilum-specific IgG 
and IgM in paired serum samples collected at 8 and 
28 days after tick removal [74]. The remaining studies 
only evaluate exposure risk [49, 71–73], rather than 
follow-up of those patients bitten by infected ticks. In 
the absence of patients’ follow-up, the results are dif-
ficult to interpret. However, the difference between 
high prevalence in ticks (e.g. 23.7% in Poland) and 
the patients not coming back for a medical consulta-
tion, together with the relative low number of reported 
cases, may be explained by a low transmission rate, 
asymptomatic cases or undiagnosed mild infection. 
Another suggested explanation for this discrepancy was 
the blood meal, which may trigger bacterial reactiva-
tion in infected ticks [71].
Beyond tick bite transmission, human infections have 
followed blood or red cell transfusions in both the USA 
and Europe [59, 75, 76]. Although only a single infection 
case of transfusion-acquired HGA has been described 
in Europe [75], several countries such as Poland and 
Belgium have reported blood donor seroprevalence to 
be high (5.4 and 14.5%, respectively), consequently the 
risk of infection via blood transfusion should be further 
investigated [77, 78].
Perinatal transmission from mother to child has only 
been described in the USA [79, 80]. The timing of neona-
tal infection was consistent with three potential transmis-
sion routes (intrauterine/transplacental, during the birth 
or through breast feeding); however, the transplacental 
route was suggested as being the most probable [81]. In 
Europe, transplacental transmission has been demon-
strated in both cows and sheep [81, 82], and it was also 
suggested for dogs infected with a different Anaplasma 
species (i.e. A. platys) from Europe [83] and Africa [84].
Nosocomial exposure to HGA by direct contact with 
blood or respiratory secretion from a fatal HGA case 
was suggested only once in a Chinese hospital [85], but 
other authors contested the hypothesis, due to insuffi-
cient evidence [86]. Moreover, later it was confirmed that 
all patients had severe fever with thrombocytopenia syn-
drome virus (SFTSV) infection [87]. This agent, a newly 
discovered bunyavirus, causes a clinical picture which 
resembles previously described Chinese HGA cases [85, 
87]. Subsequently, the possibilities of SFTSV and HGA 
co-infection or HGA misdiagnosis were debated in a 
series of comments and responses [88, 89]. In addition, 
by comparing the clinical picture of USA HGA cases 
with Chinese HGA cases and arguing the slight chances 
for simultaneous infection with both infectious agents, 
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Wormser [90] impugned the accuracy of the diagnostics 
in reported Chinese cases.
Human granulocytic anaplasmosis in Europe
Geographical distribution and epidemiological indices
HGA was first diagnosed in 1990, in Wisconsin (USA) 
in a patient with tick bite history and severe febrile ill-
ness [11]. In Europe, the first human clinical case was 
described in Slovenia in 1997, but evidence of human 
infection pre-dated this back to 1995 in Switzerland and 
the UK [91–93]. Subsequently, HGA has been reported 
in several European countries (Fig.  1): Austria [94, 95]; 
Belgium [78, 96]; Croatia [97, 98]; Czech Republic [99, 
100]; France [101, 102]; Germany [103]; Italy [22, 104]; 
Portugal [105]; the Netherlands [106]; Norway [107, 
108]; Poland [109, 110]; Slovakia [111, 112]; Spain [113]; 
and Sweden [114]. The geographical distribution of A. 
phagocytophilum reported herein being based upon case 
reports, serological surveys or genetic studies.
The incidence of human HGA cases in Europe is lower 
(estimated under 300) than reported from the USA, 
where a steady increase has been reported since 2001, 
with more than 15,000 accumulated cases until 2015 [59]. 
This difference cannot be explained by pathogen preva-
lence in ticks as A. phagocytophilum is reported in some 
3% of European I. ricinus, nearly as high as that among 
ticks in the USA [115]. On a cautionary note, the major-
ity of studies do not provide sufficient data regarding the 
prevalence of each ecotype/genotype circulating in ticks 
and humans, potentially masking prevalence of potential 
zoonotic strains.
Human seroprevalence in Europe is on average ~ 8.3%, 
reaching up to 31% (Table 2). This incongruence between 
human seroprevalence and observed clinical cases might 
arise from incomplete diagnosis, or a high rate of asymp-
tomatic infections [116], or serological cross-reactivity 
that might lead to an overestimation of seroprevalence 
rate [115]. This disparity is partially explained by Swedish 
studies in which more than half of the patients with an 
ongoing A. phagocytophilum infection (seroconversion 
or 4-fold increased antibody titre), failed to develop any 
other associated clinical symptoms upon follow-up inter-
view, being defined as having subclinical infection [116].
Reported seroprevalence appears highly variable, 
depending on the study, country, year and population 
included (Table  2). The majority of summarised studies 
refer to seropositive individuals in accordance with the 
probable case definition: serological evidence of elevated 
IgG antibody reactive with A. phagocytophilum antigen 
by IFA, with a cut-off of 1:64 (CDC case definitions of 
Anaplasma phagocytophilum infection). In the major-
ity of these studies, serological testing was performed 
using commercial IFA kits utilising human isolates of A. 
phagocytophilum (different strains) cultivated in HL60 
cells as antigen, with a cut-off value of 1:64. For the stud-
ies in which other serological assays or other criteria for 
interpretation were used, the details are provided.
Bakken et  al. [107] compared HGA seroprevalence 
between Lyme borreliosis (LB) patients (study group) and 
healthy people (control group) in Norway. A total of 58 
patients diagnosed with LB were tested for the presence 
of antibodies against A. phagocytophilum (at that time 
known as “Ehrlichia equi”) using Ehrlichia equi infected 
neutrophils as antigen. Values ≥ 1:80 were considered 
positive. The study group included patients with a pre-
sumed recent I. ricinus bite and serologically-confirmed 
active LB [107]. The results indicated that 10.34% of the 
patients were seropositive for both HGA and LB, show-
ing that patients with LB were 5.28 times more likely to 
have had HGA than the control subjects [107]. Dumler 
et al. [114] published a similar survey on Koster Islands 
(Sweden). They tested randomly the population for the 
presence of HGA using the same protocol as described 
by Bakken et  al. [107], and LB antibodies and found 
among the 21 HGA seropositive residents, six were 
seropositive also for LB [114]. Both these studies con-
sidered as seropositive patients with elevated antibody 
titer (≥ 1:80), having lower probability for non-specific 
reactivity compared to studies using lower titer (≥ 1:64). 
However, in both studies the results showed the presence 
of both HGA and LB antibody, without the confirmation 
of HGA, suggesting not necessarily a high probability of 
co-infection, but the increased contact risk with both 
pathogens. Since the vector is the same for both, the 
results indirectly showed an increase of seropositivity in 
individuals with high risk to tick exposure. This is also 
sustained by the results of an extensive study published 
by Pusterla et  al. [117] involving 1515 individuals from 
Switzerland, stratified into groups according to their risk 
for tick exposure. Low risk groups included newborns, 
and randomly chosen blood donors with unknown tick 
exposure rate and a high-risk group comprised of hunt-
ers and those with other tick-borne infections. Serum 
samples were examined by IFA using a 1:80 cut-off value 
for antibodies against A. phagocytophilum (bovine leu-
cocytes infected with “Ehrlichia phagocytophila” Swiss 
strain). Only 0.54% of the newborn samples had positive 
titres, potentially reflecting maternal antibodies, whereas 
1.1% of blood donors were seropositive and for the high-
risk group 9% seroprevalence in hunters; those with LB 
yielded 12.7%; whereas TBE cases revealed 19.5% sero-
positive for HE [117]. In addition to the studies in Nor-
way and Sweden [107, 114], this study [117] showed high 
prevalence of HGA antibody in all tested high tick expo-
sure risk groups, all suggesting the high exposure to ticks 
as a risk factor for HGA. The different seroprevalence 
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between the tick exposed groups (hunters vs LB or TBE 
patients) may suggest also an increased risk for co-infec-
tion with other pathogens transmitted by I. ricinus. This 
is also sustained by other studies from other countries. In 
Slovakia, between 2002 and 2005, from 76 patients with 
a history of tick bite and symptoms resembling LB, 19 
Table 2 The seroprevalence of HGA in different tick exposure risk groups in Europe
Abbreviations: Ab, antibody; TBD, tick borne disease; EM, erythema migrans; LB, Lyme borreliosis; Seq, sequencing
Country Location Prevalence (%) Total examined Group Method References
Austria Tyrol 2.62 191 TBD suspected IFAT [94]
Belgium – 30.96 1350 TBD suspected IFAT [96]
Belgium Walloon 14.20 148 Exposed workers ELISA [82]
Namur 17.20 209 Blood donors
Brussels 14.50 193 Blood donors
Czech Republic Central Bohemia 15.15 66 EM patients PCR; Seq [100]
18.18 66 EM patients IFAT
France – 0.01 141,007 IFAT [125]
– 1.01 399 PCR
France Alsace 20.00 15 IFAT; PCR [102]
France Alsace 2.60 2908 Forest workers ELISA [123]
Lorraine 1.30
Champagne‑Ardenne 1.40
Bourgogne 1.00
Franche‑Comté 2.30
Germany – 4.51 422 Ab to B. burgdorferi IFAT [104]
– 1.20 249 Control group IFAT
Italy – 6.33 79 IFAT [105]
Norway Telemark 10.34 58 LB patients IFAT [107]
1.96 51 Control group
Norway Sogn og Fjordane 16.28 301 Blood donors IFAT [127]
Poland Pulawy 26.10 46 Forest workers IFAT [122]
Lubartów 35.90 39
Lublin 23.30 30
Sobibór 17.00 47
Zwierzyniec 23.60 55
Goscieradów 13.60 44
Lublin 5.4 56 Blood donors
Poland Lublin 20.63 63 Forest workers IFAT [119]
Poland – 9.1 450 Endemic area IFAT [120]
2 50 Blood donors
Poland Białystok 3.9 231 Forest workers IFAT [121]
Poland Roztocze 17.7 113 Forest workers IFAT [76]
Lublin 5.4 56 Blood donors
Poland – 10.91 110 TBE PCR [110]
Slovakia – 25 76 TBD suspected IFAT [111]
Slovenia – 60.87 46 PCR; Seq [32]
Sweden Koster Island 11.35 185 IFAT [114]
Sweden – 9.70 206 TBD suspected IFAT [116]
Switzerland – 0.54 373 Newborns IFAT [81]
1.13 530 Blood donors
8.91 258 Hunters
12.75 149 Ab to B. burgdorferi
19.51 205 Ab to TBE
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(25%) were seropositive, having ≥ 1:64 IgG antibody titer 
against A. phagocytophilum. Among these positives, 14 
were additionally seropositive for LB [111]. In Germany, 
Kowalski et  al. [104] conducted an 8-year (1994–2001) 
seroprevalence study in Berlin/Brandenburg, north-
eastern Germany. They compared 422 sera from patients 
with a confirmed tick-bite (positive antibodies against B. 
burgdorferi) with 249 control sera positive for antibod-
ies against a different spirochaete (Treponema pallidum) 
or against different obligate intracellular bacteria (Chla-
mydia spp.). As in other studies, among the LB antibody-
positive specimens there were significantly more A. 
phagocytophilum antibody-positive samples (4.5%) than 
among controls (1.2%) [104]. However, without confir-
mations of HGA cases these results alone cannot confirm 
the hypothesis.
In addition to these serological data, three other studies 
described confirmed co-infections through seroconver-
sion or DNA detection. An Italian study on 79 patients 
with tick bite history within 6 months and/or who were 
presented to hospital with a suspected tick-borne infec-
tion or aseptic meningitis yielded five cases (6%) with 
a positive HGA serology [118]. Among these, two were 
confirmed HGA cases (fever and seroconversion with 
a 4-fold change in serum antibody titer to A. phagocyt-
ophilum), one was a probable HGA case (fever and acute 
and convalescent serum samples with unchanging IFA 
titer), two patients had a possible HGA infection (serum 
samples with a titer of ≥ 1:128 at only the testing point), 
whilst three individuals had positive serology for LB. 
Moniuszko et  al. [110] published a report on the pres-
ence of A. phagocytophilum, Borrelia and Babesia spp. 
DNA in the blood of 110 TBE (meningitis/encephalitis 
and positive serology) patients in Poland, comparing the 
results with a control group of 20 healthy blood donors. 
A prevalence of 10.9% A. phagocytophilum-TBEv co-
infection was recorded and 2.7% for triple co-infection 
(TBEV–Borrelia sp.–A. phagocytophilum). Similarly, 
in Czech Republic, among 66 patients with erythema 
migrans (EM) twelve (all with positive PCR for B. burg-
dorferi (s.l.)) were seropositive by IFA IgG to HGA and 
ten (nine with positive PCR for B. burgdorferi (s.l.)) were 
PCR-positive from blood or skin samples [100]. Among 
14 A. phagocytophilum and B. burgdorferi (s.l.) co-
infected patients (confirmed by DNA detection), three 
were pregnant women; one subsequently aborted and the 
mother’s blood sample was positive for both A. phagocyt-
ophilum and B. garinii DNA. The two other women safely 
delivered, although one had A. phagocytophilum-positive 
blood and placenta, and the other B. garinii-positive 
skin, A. phagocytophilum-positive blood and B. garinii-
positive placenta [100]. Despite the case confirmation 
through A. phagocytophilum DNA isolation, both these 
studies used 16S rRNA gene fragment amplification and 
provided no data regarding the sequence analysis and the 
strain involved.
Similarly, high HGA seroprevalence was associated 
with occupational risks and/or populations living in 
endemic areas, with multiple cases reported. Tomasie-
wicz et  al. [119] compared the HGA seroprevalence in 
63 individuals with occupational exposure to tick bites 
(forest workers) and with tick bite history, with a blood 
donor control group (n = 30) from Poland. A seropreva-
lence of 20.6% was found for among the tick exposed 
group, with the vast majority (85%) also additionally 
having anti-B. burgdorferi antibodies. In contrast, none 
of the blood donors were seropositive. Grzeszczuk et al. 
[120] tested for HGA antibodies from 450 serum sam-
ples originating from north-eastern Poland (known to 
be endemic for LB and TBE) which were submitted for 
serological diagnosis of LB. The study included a control 
group comprised of 50 healthy blood donors. The HGA 
seroprevalence was 9.1% for people living in the endemic 
area, compared to 2% in healthy blood donors. A sig-
nificant difference was found between forest workers 
(16.7%) and other occupational categories (4.6%). Similar 
serological findings were reported from other studies in 
Poland [77, 121, 122]. Cisak et al. [77] and Chmielewska-
Badora et al. [122] reported a high seroprevalence (17.7% 
and 23%, respectively) in forestry workers compared with 
the control group consisting in healthy blood donors 
(5.4% in both studies) in Lublin region. Grzeszczuk et al. 
[121] reported a low seroprevalence (3.9%) in both for-
estry and office workers in Białystok vicinity [121].
In all Polish studies, a cut-off value of 1:64 was used, 
increasing the risk for non-specific reactivity, in this 
case the true seroprevalence being lower. Nevertheless, 
the differences between exposed and control popula-
tions may be still sustained by the obtained data. The 
low seroprevalence observed by Grzeszczuk et al. [121] 
compared with other studies [77, 122] may sustain the 
presence of endemic and non-endemic areas in Poland. 
However, despite these three studies using the same 
serology kit and cut-off value, a comparison between 
them is not possible since in the study by Grzeszc-
zuk et  al. [121] a control group was not tested. A low 
A. phagocytophilum seroprevalence was also reported 
in a survey on a high risk population (forestry work-
ers, which are in general tick exposed) in north-eastern 
France, using an anti-A. phagocytophilum recombinant 
P44 antigen IgG ELISA, and IFA re-tested of doubtful 
or positive sera [123]. This ELISA technique was previ-
ously tested and showed a sensitivity of 87% at a 1:160 
cut-off value and a specificity of 98%, being comparable 
to IFA procedures for the laboratory diagnosis of HGA 
[124]. From a total of 2908 forestry workers, only 1.7% 
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were seropositive; however, regional variation with a 
higher seroprevalence (2.6%) was reported from Alsace 
[123]. This finding was consistent with previous find-
ings according to which Alsace may be a focal endemic 
area [125]. During a ten-year study in France, involv-
ing 141,007 patients with a history of tick bite, sera 
were tested using a micro-immunofluorescence assay. 
Titres of ≥ 1:100 for IgG and ≥ 1:50 for IgM in acute 
phase serum and/or the presence of seroconversion 
were considered for the positive cases. Only one HGA 
case was diagnosed from 112,995 tested sera samples 
from 2000–2008, whereas five new confirmed cases of 
HGA among the 14,000 tested sera were identified in 
2009 [125]. Similarly, from a total of 261 samples tested 
for A. phagocytophilum DNA using molecular diagnos-
tic assays during 2000–2008, only one HGA case was 
diagnosed, whereas three new cases of HGA among the 
81 samples were identified in 2009 [125]. All PCR con-
firmed HGA cases originated from Alsace, from where 
only nine samples were tested in total [125], highlight-
ing the existence of focal endemic areas. Despite the 
amplification and sequencing of 16S rRNA confirmed 
the infection, this conserved gene is not useful for 
genotyping, providing little information regarding the 
genetic variants involved in these cases.
In contrast with the suggested influence of diverse fac-
tors on the HGA seroprevalence, other studies seem to 
report no difference between the different risk categories. 
In Belgium, among 148 samples from workers who were 
professionally exposed to tick bites (veterinarians, farm-
ers, hunters, and gamekeepers), 209 samples from rural 
blood donors and 193 samples from urban blood donors 
tested by IFA, a high A. phagocytophilum seroprevalence 
was observed, suggesting the presence of endemic areas 
in the country. Seroprevalence of A. phagocytophilum 
was estimated as 14.2% for the exposed workers, 17.2% 
for the rural blood donors, and 14.5% for the urban blood 
donors [78]. Even if a low cut-off value (1:64) was used, 
this high seroprevalence is sustained by another study 
from Belgium [96]. Among 1350 patients suspected of a 
tick-borne infection between 2000 and 2009, 418 (31%) 
of patients were found positive for either IgG or IgM 
antibodies, using IFA against A. phagocytophilum, for 
both IgG and IgM antibody (cut-off value 1:64 and 1:20, 
respectively) [96]. Among 322 serum samples available 
for confirmation, 111 fulfilled the case definition, namely 
history of tick bite, fever, and an at least a 4-fold increase 
in IgG titre [96, 126]. Similarly, in Norway, among 301 
healthy blood donors, 49 (16.2%) were seropositive hav-
ing an antibody titer higher than 80 [127]. The authors 
observed no significant difference according to gender, 
age, geography, self-reported number of tick bites or 
presence of antibodies to B. burgdorferi (s.l.) [127].
Based on these studies, countries with a greater risk 
highlighted by a high seroprevalence are Norway, Swe-
den, Germany, Belgium, Poland and Switzerland. The 
high HGA prevalence in co-infections with pathogens 
transmitted by the same tick vectors may be explained 
by simultaneous exposure. However, based on limited 
published data, a previous infection cannot be ruled out 
especially in non-confirmed cases through fever and 
seroconversion, or a 4-fold change in serum antibody 
titer to A. phagocytophilum, and/or a positive PCR.
Clinical manifestation
Surprisingly few HGA cases have been reported from 
Europe, limiting reliable clinical description of these 
individuals. We reviewed the published data from the 76 
patients in Europe for which clinical and laboratory data 
were available (Table 3) [111, 128, 129].
Age of patients varied between 5–70 years-old with a 
median of 53.5. Most of them (78.8%), recalled tick bite 
between 3–30  days (mean 12.7) before the onset of the 
disease, with most cases occurring between April and 
October. Determination of the duration and magnitude 
of bacteraemia in humans with HGA is challenging as 
laboratory examination is rarely undertaken during the 
early acute phase of infection. In a Slovenian study, the 
febrile period of the first five confirmed HGA cases had 
a mean of 7.5  days [130]. European HGA cases tend to 
present with mild or even asymptomatic infection, with 
complete recovery in two weeks, even in the absence of 
specific treatment [131]. Transient infection may occur 
in the absence of associated clinical signs; consequently, 
cases may not always be detected. However, among the 
patients included in this analysis, 62.8% were hospital-
ized, 73.1% received specific treatment and only in one 
report, two patients were asymptomatic. This discrepancy 
might relate to selective publishing bias with over-report-
ing of more severe clinical cases. Clinical presentation 
was usually as an acute non-specific febrile infection. 
Of those infected, 79.3% presented with pyrexia, 89% 
headache, 67.6% fatigue or malaise, 63.3% myalgia, 
56.6% arthralgia and 39.2% with nausea. However, fever 
is more often reported. Considering the vast major-
ity of the reports, the frequency of fever varies between 
90–100%. One study [111], in which fever was reported 
in only 26.3% of the serologically confirmed cases can 
be considered doubtful since the authors refer to sero-
logically confirmed cases but provide no data regarding 
the confirmation method. However, the authors report 
other clinical signs consistent with HGA infection and/
or HGA and LB co-infections. Nevertheless, it is not 
clear if the reported cases are in acute or convalescent 
phase. Other clinical observation were: digestive signs 
(51.5%, including vomiting, diarrhea, abdominal pain, 
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splenomegaly, hepatomegaly); exanthema/rash (23.8%); 
conjunctivitis (21.2%); lymphadenopathy (21.2%); cough 
(17.5%, including two cases of interstitial pneumonia, one 
atypical pneumonia, one case of ARDS-acute respiratory 
distress syndrome); neurological signs (15.5%, including 
vertigo in most of the cases, one case of facial palsy; one 
case of meningeal signs, one case of aseptic meningitis); 
and cardiac signs (tachycardia and hypotension in one 
case; one case of systolic murmur). The presence of ery-
thema/rash was reported mainly in patients with LB or 
seropositive for B. burgdorferi (s.l.). However, there are 
reports in which co-infections are not specified [132] or 
are excluded [133]. In this last study, the patient devel-
oped a diffuse rash while acute and convalescent sera 
were negative for antibodies against B. burgdorferi, Cox-
iella burnetii, Rickettsia conorii, R. typhi, Mycoplasma 
pneumoniae, Leptospira, Chlamydia pneumoniae and Ch. 
psittaci [133]. Fatal infections are rare, but infection can 
cumulate in multi-system failure [59]. Co-infection with 
other tick-borne pathogens should be considered. Almost 
a third of HGA patients were additionally seropositive for 
B. burgdorferi (s.l.), less for Ehrlichia chaffeensis and two 
patients had concurrent TBE. The presumed co-infection 
with E. chaffeensis was not proven by DNA detection in 
these cases [129], suggesting a cross reaction. However, 
seroreactivity to E. chaffeensis in the absence of A. phago-
cytophilum antibody has been occasionally reported in 
the European human population [98], and one patient in 
Serbia was recognized to have clinical illness [134].
Cases acquired in Europe share the same clinical pic-
ture observed in USA, however, European cases are 
generally milder and thus far no fatalities have been 
reported. There is evidence of higher strain heterogeneity 
in Europe [21] that could correlate with host preference, 
pathogenesis and resulting virulence in humans [16]. 
This hypothesis is sustained by experimental infection in 
lambs with different A. phagocytophilum variants show-
ing different pathogenic traits [135, 136]. In addition, fac-
tors related to different species of vectors may influence 
the virulence in an analogous situation as that between 
American and European B. burgdorferi strains [137].
Diagnosis
According to the Centre for Disease Control and Preven-
tion (CDC, Atlanta, Georgia, USA), confirmatory crite-
ria for patients with consistent clinical presentations are 
either detection of A. phagocytophilum DNA in a clini-
cal specimen via PCR amplification of a specific target, 
demonstration of Anaplasma antigen in a biopsy/autopsy 
sample by immunohistochemical methods, or isolation 
of A. phagocytophilum from a clinical specimen in a cell 
culture system. Serologically, a 4-fold change in antibody 
titre (IgG) against A. phagocytophilum antigen by IFA 
in paired (2–4  weeks) serum samples is confirmatory. 
Although for European HGA, there is no official case def-
inition yet, both the European Centre for Disease Con-
trol and Prevention (ECDC) and the European Society 
of Chlamydia, Coxiella, Anaplasma and Rickettsia, for-
merly ESCAR: ESCMID Study Group on Coxiella, Ana-
plasma, Rickettsia and Bartonella (ESCCAR) guidelines 
are in concordance with the CDC guidelines.
Diagnosis of HGA should be based on clinical signs 
and patient’s history and can be supported by laboratory 
confirmatory tests. As described above, the symptoms of 
HGA may vary from patient to patient and can be diffi-
cult to distinguish from other conditions, especially other 
tick-borne diseases. Information such as recent tick bite, 
exposure to areas where ticks are likely to be found, or a 
history of recent travel to areas where HGA is endemic 
can be helpful in supporting the diagnosis. However, 
since A. phagocytophilum is endemic throughout Europe, 
the appropriateness of this latter criterion is limited. 
Routine blood tests, such as a complete blood cell count 
or a chemistry panel may be useful since thrombocytope-
nia, leukopenia or elevated liver enzyme levels are help-
ful predictors of anaplasmosis but may not be present in 
all patients. Common laboratory findings were: elevated 
CRP in 93.03%; elevated liver enzymes in 90% (alanine 
transaminase level; aspartate transaminase level); throm-
bocytopenia in 83.7% and leukopenia in 63%. Less com-
monly, in less than 50% of the cases the levels of lactate 
dehydrogenase and neopterin were increased, associ-
ated with elevated erythrocyte sedimentation rate and 
increased serum bilirubin [128].
Once clinically suspected, specialised laboratory test-
ing should be undertaken for HGA confirmation. Indi-
rect immunofluorescence using A. phagocytophilum 
whole antigen is often considered the gold standard sero-
logical test for diagnosis of HGA. Use of paired serum 
samples enables demonstration of a significant rise 
(4-fold) in antibody titres, using a cut-off value of at least 
1:64 [126]. Ideally, the first sample should be collected 
in the first week of illness (during the acute phase) and 
the second and/or third between two to four weeks later 
[126]. IgM antibodies are less specific than IgG antibod-
ies and are more likely to generate false positive results. 
Moreover, IgM results alone should not be used for lab-
oratory diagnosis due to the low sensitivity [126, 138]. 
Serological tests based on enzyme immunoassay (EIA) 
technology are commercially available. IFA is generally 
used for screening and confirmation of HGA cases. The 
most commonly used commercial kit for IgG detection 
in the studies summarized in this review was from Focus 
Technologies, USA. According to the manufactures, the 
specificity of this test reaches 100%, and the sensitivity 
depends on the period between the moment of sampling 
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and the beginning of the clinical signs, which ranges from 
66.7% to 100% at a cut-off value of 1:64. Similarly, other 
IFA IgG kits have an 80–86.6% sensitivity and 92.7% 
specificity [126]. The ELISA technique was used only in 
few reports. The performance characteristics were evalu-
ated by Ijdo et al. [124], showing an 87% sensitivity at a 
1:160 cut-off value and a specificity of 98%, being com-
parable to IFA procedures [124]. However, this technique 
has been used in a limited number of studies provid-
ing insufficient support for routine use in diagnostic 
laboratories.
Acute phase whole blood samples can be tested by 
PCR targeting various genes such as 16S rRNA or msp2 
[139]. This method is most sensitive in the first week of 
illness, but rapidly decreases in sensitivity following the 
administration of appropriate antibiotics. The analysis of 
published HGA cases in Europe (see above) have shown 
a relative low percent 68.2% of positive PCR results. 
Similarly, among 46 Slovenian confirmed cases of human 
anaplasmosis compatible with ESCCAR guidelines, only 
28 (60.9%) of them were positive for the presence of A. 
phagocytophilum DNA [139]. Thus, a positive PCR result 
may be helpful, but a negative result does not exclude the 
diagnosis, and treatment should not be withheld due to 
a negative PCR result. In addition to acute phase sam-
ple collection time, the sensitivity of molecular detec-
tion also depends on: (i) sample type and quality, full 
blood or buffy coat being considered the more suitable 
compared with plasma [139] because of the tropism of 
A. phagocytophilum for white cells; and (ii) the number 
of genomic target gene copies and the amplicon length 
(short sequences being generally preferred to long ones 
for screening; longer ones being more used for sequenc-
ing and phylogenetic analysis) [139]. Most frequently 
used target genes for Anaplasma spp., include 16S rRNA 
(rrs), heat-shock protein (groEL), citrate synthase (gltA), 
and major surface proteins (msp1, msp2, msp4, msp5). 
For molecular screening, the sensitive multicopy msp2 is 
particularly useful, whereas for sequence comparison and 
database crossmatch, conservative or moderately con-
servative rrs and groEL strategies are regarded as a better 
choice [139].
During the first week of illness, a microscopic examina-
tion of blood smears may reveal morulae of A. phagocy-
tophilum in the cytoplasm of the neutrophils. However, 
the percent of patients presenting intracytoplasmic 
morulae in the acute phase may vary from low values in 
Europe [129] to high values of 25–60% or even more in 
the USA [140, 141]. Although sensitivity is limited, this 
can be improved if the smear is performed from the 
buffy coat [139]. Gram staining is not suitable to visualize 
intracellular bacteria because of a lack of contrast against 
the host cytoplasm. Romanowsky staining is generally 
used, usually with a quick method such as Diff-Quik. This 
approach stains the bacteria purple, which allows the vis-
ualization of characteristic morulae. Morulae are usually 
1.5–2.5 µm in diameter but can be as large as 6 µm [140].
Similar with the DNA detection, in vitro cultivation 
may be used also in the acute phase of illness. Cultivation 
of A. phagocytophilum from human blood has been used 
since 1996, when Goodman et al. [142] successfully iso-
lated the bacterium on HL-60 cells. More recently, cul-
tivation from blood was also successfully achieved from 
two patients from Czech Republic [100].
Treatment
Chemical prophylaxis is not recommended after a tick 
bite, even in endemic regions [131]. Doxycycline is con-
sidered the drug of choice with good results for HGA in 
adults as well as in children older than eight years. Treat-
ment should be instituted on clinical suspicion alone 
to avoid the potential for serious complication, [59]. 
Doxycycline (100  mg twice daily by IV or PO between 
10–14  days) is highly effective and post-therapeutic 
relapses have not been reported [59, 143]. There is gener-
ally a rapid response to treatment with a marked clinical 
improvement within 24–48  h [59]. A possible alterna-
tive for children and patients with a doxycycline allergy 
or pregnant women is rifampicin with the following 
dose: for children 20  mg/kg/day, maximum 600  mg in 
two doses PO and for adults 300 mg, twice 2 times daily 
PO for 5–7 days in both cases [59, 144]. Other antibiot-
ics, such as quinolones, cephalosporin’s, penicillin’s, and 
macrolides are ineffective [143]. To prevent infection, 
precautions should be taken to avoid exposure to ticks.
Gaps remaining
Despite the great efforts of researchers for a better char-
acterisation of HGA and A. phagocytophilum in Europe, 
there are several gaps remaining. The majority of them 
are related with the ecology and genetic diversity and 
their correlation with the pathogenicity.
First of all, it is important to be established how much 
the terms of different genetic variants (e.g. clusters, 
ecotype or genotype) are overlapping. The authors used 
different terms for these variants according to the gene 
analysed or maybe to their own preferences. However, for 
a better understanding of the pathogen genetic variability 
it is necessary to reach a consensus.
Regarding the pathogenicity to humans, it is not clear 
if strains less related with the human isolates, belonging 
to different genetic groups (e.g. rodent, bird, or roe deer 
strains in Europe or AP-V1 in USA) were not detected 
in humans because they are non-pathogenic, or because 
they cause asymptomatic infections. One important 
question is if they cause or not a serological response.
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Similarly, the strains belonging to the same genetic 
group as human strains have zoonotic potential; how-
ever, it is not clear whether they have a different path-
ogenic potential for humans. Regardless of the study, 
the genetic group including human strains is the most 
diverse, clustering together strains from a large vari-
ety of hosts (Table  1). However, depending on the 
gene used, some strains (detected in sheep, goats, 
cows, hedgehogs, wild carnivores etc.) may belong to 
different groups. Because of this it is important to be 
established which approach is discriminatory enough 
to evaluate the risk for human health. Additionally, in 
order to evaluate the public health risks, the preva-
lence and geographical distribution of each genetic 
group should be further evaluated.
Another important but insufficiently clear aspect 
is the understanding of differences between HGA 
in USA and Europe. Although, there are clear differ-
ences between the ecology of American and European 
strains (e.g. different vectors, different hosts, appar-
ently different genetic variability), it is not clear if the 
ecology or the genetic differences alone influence the 
pathogenicity to humans, or whether this may influ-
ence the prevalence of infections and increase the 
risk for developing more severe forms of diseases. 
Even more unclear, and therefore an important topic 
for future research, is tackling the differences in both 
pathogenicity and ecology between European and 
Asian strains.
Other gaps are related to the diagnosis and the 
seroprevalence or prevalence of HGA. Since HGA in 
Europe is not a disease with a mandatory surveillance 
and reporting, some cases may be not published. More-
over, clinical suspicion or even serological detection 
may be not be followed by confirmatory tests but may 
be treated. In addition, the unspecific clinical picture 
may lead to underdiagnosing. In this case, the preva-
lence is estimated based on published data and thus 
influenced by researchersʼ interest and by the approach 
they used. In addition, in the absence of mandatory sur-
veillance and an official case definition in Europe, the 
diagnostic approaches may differ between the laborato-
ries. In this case, interpretation of results interpretation 
and classification of suspected, probable and confirmed 
cases should be made with caution. Even following sup-
portive and/or confirmed laboratory criteria published 
by CDC, (e.g. IFA IgG with a cut-off of ≥ 1:64 as sup-
portive criteria, or detection of A. phagocytophilum 
DNA in a clinical specimen via amplification of a spe-
cific target in a PCR assay as confirmatory criteria), the 
published cases can be questioned if a single approach 
is used, especially if low titer of < 640 is obtained or if a 
single target gene is amplified but sequenced.
Conclusions
Despite the apparently ubiquitous presence of A. 
phagocytophilum in ticks and various wild and domes-
tic animals from Europe, published clinical cases of 
HGA remain rare, currently only a few hundred. It is 
unclear if this reflects the incidence of human infection 
in Europe or if the disease is underdiagnosed or under-
reported. Epidemiologic studies in Europe have sug-
gested an increased occupational risk of infection for 
forestry workers, hunters, veterinarians, and farmers 
with a tick-bite history and also those living in endemic 
areas. Another risk factor for HGA seems to be infec-
tion with other pathogens transmitted by I. ricinus, 
mainly B. burgdorferi (s.l.). Although the overall genetic 
diversity of A. phagocytophilum in Europe seems to 
be higher than in the USA, the strains responsible for 
human infections are related on both continents, hence 
a difference in pathogenicity seems unlikely. However, 
to date, the study of the genetic variability and assess-
ment of the difference in pathogenicity and infectivity 
between strains to various hosts has been insufficiently 
explored.
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